Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.

@article{File2001EfficacyAS,
  title={Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.},
  author={ThomasM. File and Beno{\^i}t Schlemmer and Javier Garau and Michael A Cupo and Carolyn C Young},
  journal={The Journal of antimicrobial chemotherapy},
  year={2001},
  volume={48 1},
  pages={
          67-74
        }
}
This multicentre, randomized, double blind, parallel group study compared the efficacy and safety of gemifloxacin (320 mg once daily) with trovafloxacin (200 mg once daily) in 571 patients with community-acquired pneumonia (CAP). Although treatment was given routinely for 7 days it could be extended to 14 days; two-thirds of patients were treated for 7 days. High clinical success rates were noted at follow-up in the per-protocol population in both the gemifloxacin group (95.8%) and the… CONTINUE READING
BETA

Similar Papers

Loading similar papers…